Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

Article Abstract:

Infants who are infected with HIV at birth should begin treatment with AIDS drugs within the first few months of birth. Researchers tested the combination therapy of zidovudine, didanosine and nevirapine in eight infants who had been infected at birth. Six infants began treatment before their fifth month. Analysis of blood samples revealed that the treatment substantially reduced levels of the virus as measured by viral RNA. In seven infants, the reduction was greater than 95%. Viral RNA levels began to rise again in five infants, who were shown to have viral strains resistant to the drugs.

Author: Luzuriaga, Katherine, Sullivan, John Lawrence, Robinson, James, Bryson, Yvonne, Krogstad, Paul, Stechenberg, Barbara, Lamson, Michael, Cort, Susannah
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
Evaluation, Drug therapy, Zidovudine, Didanosine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A trial of three antiretroviral regimens in HIV-1-infected children

Article Abstract:

The safety, tolerability, and the activity of three regimens of antiretroviral therapy in HIV-1-infected children, phase 1-2 trial are evaluated. The results indicate that the children who received stavudine, lamivudine, nevirapine and nelfinavir had plasma HIV-1 RNA levels of less than 400 copies per milliliter as compared to those who received reverse-transcriptase inhibitors alone.

Author: Mofenson, Lynne, Luzuriaga, Katherine, Sullivan, John Lawrence, McManus, Margaret, Britto, Paula, Graham, Bobbie
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
United States, Science & research, Children, Health aspects, Care and treatment, Research, HIV infection, HIV infections, Antiviral agents, Antiretroviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The changing face of pediatric HIV-1 infection

Article Abstract:

The use of combinations of AIDS drugs that include a protease inhibitor have dramatically reduced mortality rates among HIV-infected children and teenagers. However, most new HIV infections in children occur in developing countries that cannot afford most AIDS drugs.

Author: Luzuriaga, Katherine, Sullivan, John Lawrence
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
Editorial, Patient outcomes, Mortality

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: HIV infection in children, Pediatric HIV infections
Similar abstracts:
  • Abstracts: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. part 2 Human immunodeficiency virus infection in tuberculosis patients
  • Abstracts: Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. Treatment of adult T-cell leukemia-lymphoma with combination of interferon alfa and zidovudine
  • Abstracts: Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Natural history of opportunistic disease in an HIV-infected urban clinical cohort
  • Abstracts: The usefulness of diagnostic bone marrow examination in patients with human immunodeficiency virus (HIV) infection
  • Abstracts: Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected patients. Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.